전립선자료실 > 전립선 자료실

• 목록

수개월 전부터 고혈압(내원 당일 170/100)과 전립선 약만 복용중 우연히 검사한 경직장 전립선 초음파 검사상 전립선의 비대와 결절 그리고 사정관낭종과 사정관이 탈락된 상피세포로 좁아져 정낭의 순환 장애를 일으키는 경직장 전립선 초음파 사진입니다.(NIH :15)

This transrectal prostate ultrasound image was taken during the patient’s first visit.

The patient had been taking medication only for high blood pressure (170/100 mmHg on the day of the visit) and prostate symptoms for several months. During a routine examination, this ultrasound study was performed.

The image shows enlargement of the prostate with nodules, as well as an ejaculatory duct cyst. The ejaculatory duct is narrowed by shed epithelial cells, reducing its diameter by approximately 60%.

This narrowing is causing impaired circulation of the seminal vesicles, which may be related to the patient’s symptoms (NIH symptom score: 15).

사정관의 입구가 좁아져 사정관의 낭종이 진행되는 초음파 사진입니다.

This ultrasound image shows narrowing of the opening of the ejaculatory duct, which is causing the progression of an ejaculatory duct cyst.

The narrowing interferes with normal fluid flow, allowing the cyst to gradually enlarge over time.

사정관의 입구가 좁아져 정낭과 정관등의 순환 장애로 정관을 통해 사정관으로 사출될 정자들이 사정되지 못하로 정낭으로 역류하여 다발성 정낭과 혈정액과 정낭의 결석등을 일으키는 초음파 사진입니다.

This ultrasound image shows narrowing at the opening of the ejaculatory duct, which causes circulatory flow problems in the seminal vesicles and vas deferens.

Because of this blockage, sperm that should normally be ejaculated through the ejaculatory duct cannot pass properly. Instead, they flow backward into the seminal vesicles, leading to multiple seminal vesicle cysts and sometimes blood in the semen (hematospermia) and intermittantly caculi formation.

내원당일 혈액학적 PSA (Porstate Specific Antigen) 검사상 10.42 ng/mL로 수치가 증가된 자료 입니다.

On the day of the first visit, the blood test revealed that the PSA (Prostate-Specific Antigen) level was elevated to 10.42 ng/mL, which can be associated with prostate inflammation, enlargement, or other prostate-related conditions.

주 2회 전립선과 사정관, 정낭 그리고 정관등의 표적 치료후 치료된 혈정액등의 현미경학적 자료 입니다.

This microscopic image demonstrates that blood components previously present in the semen have improved following twice-weekly targeted treatment of the prostate, ejaculatory ducts, seminal vesicles, and vas deferens.

주 2회 전립선과 정낭 그리고 정관등의 표적 치료후 탈락된 상피세포와 혈정액 그리고 염증덩어리가 치료되고 있는 현미경학적 자료입니다.

This microscopic image demonstrates that previously accumulated shed epithelial cells, blood in the semen, and inflammatory material are resolving after targeted treatment of the prostate, seminal vesicles, and vas deferens performed twice a week.

주 2회 전립선과 정낭 그리고 정관등의 표적 치료후 탈락된 상피세포와 혈정액 그리고 염증덩어리가 치료되고 있는 현미경학적 자료입니다.

This microscopic image demonstrates that previously accumulated shed epithelial cells, blood in the semen, and inflammatory material are resolving after targeted treatment of the prostate, seminal vesicles, and vas deferens performed twice a week.

횟수를 더할수록 혈정액과 염증덩어리가 감소하고 탈락되어 막혀 있던 상피세포가 치료되고 있는 현미경학적 자료입니다.

As the number of treatment sessions increases, this microscopic image demonstrates that blood in the semen and inflammatory material are steadily reducing, while the previously blocked ducts caused by shed epithelial cells are improving and reopening.

주 2회 전립선의 표적 치료후 첫날 내원 당일 PSA 혈액학적 검사 수치가 10.42 ng / mL가 한달도 안되어 4.95 ng / mL로 감소되고 혈압 또한 130/80으로 안정되고 있는 자료입니다.

After starting targeted prostate treatment twice a week, the patient’s PSA (Prostate-Specific Antigen) level, which was 10.42 ng/mL on the first visit, decreased to 4.95 ng/mL in less than one month.

At the same time, the patient’s blood pressure has stabilized, improving to 130/80 mmHg.

These findings suggest that the treatment is having a positive effect on prostate inflammation and overall systemic stability.

International patient consultation version (US / Europe)

After initiating targeted prostate treatment twice weekly, the patient’s PSA (Prostate-Specific Antigen) level, which measured 10.42 ng/mL on the initial visit, decreased to 4.95 ng/mL in less than one month.

During the same period, the patient’s blood pressure also stabilized, reaching 130/80 mmHg.

These findings indicate a favorable clinical response, suggesting improvement in prostate-related inflammation and overall physiological stability.

After starting targeted prostate treatment twice per week, the patient’s PSA (Prostate-Specific Antigen) level, which was 10.42 ng/mL at the initial visit, decreased to 4.95 ng/mL in less than one month.

During the same period, the patient’s blood pressure also improved and stabilized at 130/80 mmHg.

These changes suggest a positive response to treatment, indicating a reduction in prostate-related inflammation and an overall improvement in systemic health.

From a patient care perspective, this early improvement is considered a favorable and encouraging clinical outcome.